CytomX Therapeutics, Inc. (CTMX) Director Sells $250,100.00 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Director Frederick W. Gluck sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $25.01, for a total value of $250,100.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at $24.92 on Wednesday. CytomX Therapeutics, Inc. has a twelve month low of $10.64 and a twelve month high of $25.60. The company has a market capitalization of $957.14 and a PE ratio of -15.87.

A number of institutional investors have recently made changes to their positions in CTMX. Russell Investments Group Ltd. boosted its holdings in CytomX Therapeutics by 1.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock valued at $343,000 after acquiring an additional 292 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in CytomX Therapeutics by 17.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 117,642 shares of the biotechnology company’s stock valued at $1,824,000 after acquiring an additional 17,551 shares during the period. Rhumbline Advisers boosted its holdings in CytomX Therapeutics by 48.4% during the 2nd quarter. Rhumbline Advisers now owns 32,517 shares of the biotechnology company’s stock valued at $504,000 after acquiring an additional 10,607 shares during the period. State of Wisconsin Investment Board purchased a new position in CytomX Therapeutics during the 2nd quarter valued at about $325,000. Finally, Bank of New York Mellon Corp boosted its holdings in CytomX Therapeutics by 33.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 115,777 shares of the biotechnology company’s stock valued at $1,794,000 after acquiring an additional 29,319 shares during the period. Institutional investors own 63.13% of the company’s stock.

A number of analysts recently issued reports on the company. Citigroup assumed coverage on CytomX Therapeutics in a research report on Friday, January 5th. They set a “buy” rating and a $40.00 price objective for the company. BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 15th. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $32.78.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/10/cytomx-therapeutics-inc-ctmx-director-sells-250100-00-in-stock.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit